Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs

Veterinary and Comparative Oncology

Volumn 6, Issue 2, 2008, Pages 90-101

  Marconato, Laura ^a   Lorenzo, R M ^a   Abramo, F ^b   Ratto, A ^c   Zini, E ^d  

^a Clinica Veterinaria L'Arca   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c LIGURIA E VALLE D AOSTA   (Italy)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Chemotherapy; Dog; Gemcitabine; Mammary carcinoma; Surgery

Indexed keywords

CANIS FAMILIARIS;

ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE;

ADJUVANT CHEMOTHERAPY; ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; EXPERIMENTAL NEOPLASM; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; PROSPECTIVE STUDY; QUALITY OF LIFE; TREATMENT OUTCOME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOG DISEASES; DOGS; FEMALE; INFUSIONS, INTRAVENOUS; MAMMARY NEOPLASMS, ANIMAL; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 61749098352     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2007.00143.x     Document Type: Article

References (45)

1. Rutteman GR, Withrow SJ and MacEwen EG. Tumours of the mammary gland. In: Small Animal Clinical Oncology, 3rd edn., SJ Withrow and EG MacEwen, eds., Philadelphia, WB Saunders, 2001: 455-477.
2. Brodey RS, Goldschmidt MH and Roszel JR. Canine mammary gland neoplasms. Journal of the American Animal Hospital Association 1983;19: 61-90.
3. Ferguson HR. Canine mammary gland tumours. The Veterinary Clinics of North America 1985;15: 501-511.
4. Novosad CA. Principles of treatment for mammary gland tumours. Clinical Techniques in Small Animal Practice 2003;18: 107-109.
5. Gilbertson SR, Kurzman ID, Zachrau RE, Hurvitz AI and Black MM. Canine mammary epithelial neoplasms: Biologic implications of morphologic characteristics assessed in 232 dogs. Veterinary Pathology 1983;20: 127-142.
6. Sorenmo K. Canine mammary gland tumours. The Veterinary Clinics of North America 2003;33: 573-596.
7. Karayannopoulou M, Kaldrymidou E, Constantinidis TC and Dessiris A. Adjuvant post-operative chemotherapy in bitches with mammary cancer. Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine 2001;48: 85-96.
8. Simon D, Schoenrock D, Baumgartner W and Nolte I. Postoperative adjuvant treatment of invasive malignant mammary gland tumours in dogs with doxorubicin and docetaxel. Journal of Veterinary Internal Medicine 2006;20:1184-1190.
9. Early Breast Cancer Trialists'Collaborative Group. Polychemotherapy for early breast cancer. An overview of the randomised trials. Lancet 1998;351:1451-1467.
10. Souhami R and Tobias J. Breast cancer. In: Cancer and Its Management, 5 th edn., R Souhami and J Tobias, eds., Boston, MA, Blackwell Publishing, 2005: 216-235.
11. Pronzato P and Rondini M. First line chemotherapy of metastatic breast cancer. Annals of Oncology 2006;17: 165-168.
12. Seidman AD. Monotherapy options in the management of metastatic breast cancer. Seminars in Oncology 2003;30: 6-10.
13. Gluck S. The expanding role of epirubicin in the treatment of breast cancer. Cancer Control 2002;9: 16-27.
14. Jassem J. Gemcitabine and anthracyclines in breast cancer. Seminars in Oncology 2003;30: 11-14.
15. Bria E, Nistico C, Cuppone F, Carlini P, Ciccarese M, Milella M, Natoli G, Terzoli E, Cognetti F and Giannarelli D. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients. Cancer 2006;106: 2337-2344.
16. Ghosn M, Kattan J, Farhat F, Younes F and Gasmi J. Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients. Anticancer Research 2006;26: 2451-2456.
17. Wardley A. Capecitabine: Expanding options for the treatment of patients with early or locally advanced breast cancer. Oncologist 2006;11: 20-26.
18. Heinemann V. Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology 2003;64: 191-206.
19. Silvestris N, D'Aprile M, Andreola G, Locopo N, Marini L, Crucitta E, De Lena M and Lorusso V. Rationale for the use of gemcitabine in breast cancer. International Journal of Oncology 2004;24: 389-398.
20. Toschi L, Finocchiaro G, Bartolini S, Gioia V and Cappuzzo F. Role of gemcitabine in cancer therapy. Future Oncology 2005;1: 7-17.
21. Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WD and Dalbagni G. Toxicology and pharmacokinetics of intravesical gemcitabine: A preclinical study in dogs. Clinical Cancer Research 1999;5: 2629-2637.
22. Kosarek CE, Kisseberth WC, Gallant SL and Couto CG. Clinical evaluation of gemcitabine in dogs with spontaneously occurring malignancies. Journal of Veterinary Internal Medicine 2005;19: 81-86.
23. Moore AS and Kitchell BE. New chemotherapy agents in veterinary medicine. The Veterinary Clinics of North America 2003;33: 629-649.
24. Jones PD, de Lorimier LP, Kitchell BE and Losonsky JM. Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma. Journal of the American Animal Hospital Association 2003;39: 463-467.
25. LeBlanc AK, LaDue TA, Turrel JM and Klein MK. Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: A veterinary radiation therapy oncology group pilot study. Veterinary Radiology & Ultrasound 2004;45: 466-470.
26. Turner AI, Hahn KA, Rusk A, Gamblin RM, Cosgrove SB, Griffice K and Khanna C. Single agent gemcitabine chemotherapy in dogs with spontaneously occurring lymphoma. Journal of Veterinary Internal Medicine 2006;20:1384-1388.
27. Freise KJ and Martin-Jimenez T. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics. Journal of Veterinary Pharmacology and Therapeutics 2006;29: 137-145.
28. Freise KJ and Martin-Jimenez T. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion. Journal of Veterinary Pharmacology and Therapeutics 2006;29:147-152.
29. Misdorp W, Else RW, Hellmen E and Lipscomb TP. Histological Classification of Mammary Tumours of the Dog and the Cat. 2 nd series, Vol. VII. Washington, DC, Armed Forces Institute of Pathology, 1999.
30. Marconato L, Lindner DL, Suslak-Brown L, Nelson V and Jeglum KA. A phase I clinical trial of high dose gemcitabine in 33 dogs with transitional cell carcinoma. In: Proceedings of the 22 nd Annual Conference of the Veterinary Cancer Society 2002: 9.
31. Veterinary Cooperative Oncology Group. Veterinary cooperative oncology group -common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Veterinary and Comparative Oncology 2004;2: 194-213.
32. Okada S, Ueno H, Okusaka T, Ikeda M, Furuse J and Maru Y. Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Japanese Journal of Clinical Oncology 2001; 31: 7-12.
33. Ryan CW and Vogelzang NJ. Gemcitabine in the treatment of bladder cancer. Expert Opinion on Pharmacotherapy 2000; 1: 547-553.
34. Vogelzang NJ. Future directions for gemcitabine in the treatment of genitourinary cancer. Seminars in Oncology 2002;29: 40-45.
35. Gutheil JC and Finucane DM. Antimetabolites. In: The Chemotherapy Source Book, MC Perry, ed., Philadelphia, Lippincott Williams & Wilkins, 2001: 219-220.
36. Ferrazzi E and Stievano L. Gemcitabine: Monochemotherapy of breast cancer. Annals of Oncology 2006;17: 169-172.
37. Wirk B and Perez E. Role of gemcitabine in breast cancer management: An update. Seminars in Oncology 2006;33: 6-14.
38. O'Shaughnessy JA, Pluenneke R, Sternberg J, Khandelwal P, Ilegbodu D and Asmar L. Phase II trial of weekly docetaxel/gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer 2006;6: 505-510.
39. Fuentes H, Calderillo G, Alexander F, Ramirez M, Avila E, Perez L, Aguirre G, Onate-Ocana LF, Gallardo D and Otero J. Phase II study of gemcitabine plus cisplatin in metastatic breast cancer. Anticancer Drugs 2006;17: 565-570.
40. Goldie JH and Coldman AJ. A mathematical model for relating the drug sensitivity of tumours to the spontaneous mutation rate. Cancer Treatment Reports 1979;63:1727-1733.
41. Kurzman ID and Gilbertson SR. Prognostic factors in canine mammary tumours. Seminars in Veterinary Medicine and Surgery (Small Animal) 1986;1:25-32.
42. Hellmen E, Bergstrom R, Holmberg L, Spangberg IB, Hansson K and Lindgren A. Prognostic factors in canine mammary tumours: A multivariate study of 202 consecutive cases. Veterinary Pathology 1993;30: 20-27.
43. Philibert JC, Snyder PW, Glickman N, Glickman LT, Knapp DW and Waters DJ. Influence of host factors on survival in dogs with malignant mammary gland tumours. Journal of Veterinary Internal Medicine 2003;17:102-106.
44. Chang SC, Chang CC, Chang TJ and Wong ML. Prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumours: 79 cases (1998-2002). Journal of the American Animal Hospital Association 2005;227: 1625-1629.
45. Perez Alenza MD, Pena L, Nieto AI and Castano M. Clinical and pathological prognostic factors in canine mammary tumours. Annali dell'Istituto Superiore di Sanità 1997;33: 581-585.